Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan

Japanese Journal of Clinical Oncology

Volumn 39, Issue 4, 2009, Pages 225-230

  Kiyota, Naomi ^a   Tahara, Makoto ^a   Kadowaki, Shigenori ^a   Fuse, Nozomu ^a   Doi, Toshihiko ^a   Minami, Hironobu ^a   Ohtsu, Atsushi ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Cisplatin plus 5 FU; Head and neck cancer; Systemic chemotherapy

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BRAIN DISEASE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEAD AND NECK CARCINOMA; HEAD AND NECK SURGERY; HUMAN; JAPAN; KIDNEY DISEASE; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OROPHARYNX CANCER; OVERALL SURVIVAL; PROGNOSIS; SKIN METASTASIS; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 63849264337     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp002     Document Type: Article

References (23)

1. Cancer Mortality. Japan: Center for Cancer Control and Information Services, National Cancer Center; 2005.
2. Morton RP, Rugman F, Dorman EB, Stoney PJ, Wilson JA, McCormick M, et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: A randomised factorial phase III controlled trial. Cancer Chemother Pharmacol 1985;15:283-9.
3. Grose WE, Lehane DE, Dixon DO, Fletcher WS, Stuckey WJ. Comparison of methotrexate and cisplatin for patients with advanced squamous cell carcinoma of the head and neck region: A Southwest Oncology Group Study. Cancer Treat Rep 1985;69:577-81.
4. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study. J Clin Oncol 1992;10:1245-51.
5. Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10:257-63.
6. Forastiere AA, Leong T, Rowinsky E, Murphy BA, Vlock DR, DeConti RC, et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 2001;19:1088-95.
7. Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): An intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:3562-7.
8. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:8646-54.
9. Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994;5:521-6.
10. Vermorken JB, Hitt R, Geoffrois L, Erfan J, Kawecki A, Zabolotnyy D, et al. Cetuximab plus platinum-based therapy first-line in recurrent and/ or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety results of a randomized phase III trial (EXTREME) abstract #5501. Eur J Cancer Suppl 2007;5:324.
11. Kish J, Drelichman A, Jacobs J, Hoschner J, Kinzie J, Loh J, et al. Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck. Cancer Treat Rep 1982;66:471-4.
12. Hayashi K, Ando N, Watanabe H, Ide H, Nagai K, Aoyama N, et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: A Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol 2001;31:419-23.
13. Iizuka T, Kakegawa T, Ide H, Ando N, Watanabe H, Tanaka O, et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: A Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 1992;22:172-6.
14. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
15. Kaplan EMP. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
16. Psyrri A, DiMaio D. Human papillomavirus in cervical and head-and-neck cancer. Nat Clin Pract Oncol 2008;5:24-31.
17. D'souza G, Kreimer A, Viscidi R, Pawlita M, Fakhry C, Koch W, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-56.
18. Fakhry C, Westra W, Li S, Cmelak A, Ridge J, Pinto H, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Canc Inst 2008;100:261-9.
19. Argiris A, Li Y, Forastiere A. Prognostic factors and long-time survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 2004;101:2222-9.
20. Recondo G, Armand J, Tellez-Bernal E. Recurrent and/or metastaic head and neck cancer treated with cisplatin-based chemotherapy. Laryngoscope 1991;101:494-501.
21. Grandis J, Melhem M, Bames E. Quantitative immunohistochemical analysis of transforming growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996;78: 1284-92.
22. Dassonville O, Formento J, Francoul M. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993;11:1873-8.
23. Fan Z, Lu Y, Wu X. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 1994;269:27595-602.